Abstract：
Pancreatic adenocarcinoma (PDAC) is disease with a 5-year survival of only 12%. Many patients with PDAC present with late-stage disease and even early-stage disease can often be characterized by an aggressive tumor biology. Standard therapy for metastatic PDAC consists mainly of chemotherapy regimens like FOLFIRINOX, FOLFOX, or gemcitabine and nab-paclitaxel. Research has focused on sequencing PDAC tumors to understand better the mutational landscape and transcriptomics of PDAC with the goal to develop targeted therapies. Targeted therapies may potentially minimize the toxic risks of chemotherapy and provide a long-term survival benefit. We herein review the underlying molecular pathogenesis of PDAC, as well as the classification schema created from current sequencing data, and recent updates related to targeted therapy for PDAC.
摘要：
胰腺腺癌（PDAC）是一种5年生存率仅为12％的疾病。许多患有晚期疾病甚至早期疾病的PDAC患者通常可以以侵袭性肿瘤生物学为特征。转移性PDAC的标准治疗主要包括化疗方案，如FOLFIRINOX，FOLFOX,或吉西他滨和nab-紫杉醇。研究集中在对PDAC肿瘤进行测序，以更好地了解PDAC的突变景观和转录组学，目标是开发靶向治疗。靶向治疗可以潜在地最小化化疗的毒性风险并提供长期生存益处。我们在此回顾PDAC的潜在分子发病机制，以及从当前测序数据创建的分类模式，以及PDAC靶向治疗的最新进展。
